BDKRB2 and brain cancer: Recently, we provided evidence that dual activation of kinin B1R and B2R on the BBB by use of selective agonists, either in monomeric or dimeric form, may produce additive effects in terms of enhancing brain cancer delivery and efficacy of intraarterial carboplatin, translating into prolonged animal survival [18].